At IMMUNOMEDICS, we are committed to improving the prospects for cancer patients by developing better methods of detection, diagnosis and therapy. Although the diagnosis of cancer is a shock for the patient and family, about 4 of every 10 patients in the U.S. and Europe will be free of disease or cured five or more years after early diagnosis.

Colorectal cancer is among the most prevalent cancers, being second among those affecting both men and women. As with many other cancers, it can be managed better and lead to better survival if it is diagnosed early, when the primary tumor has not yet spread (metastasis), and if a better assessment of recurrence and extent of disease can be made during regular follow-up monitoring and choosing therapeutic options.

As medical research advances, it is our conviction that colorectal cancer will become one of the major cancers that can be treated effectively and even cured. Until that time, however, we at Immunomedics are committed to researching new methods to detect and diagnose this cancer when it is still amenable to curative surgery, and to improve current treatments by ushering in the use of the same biological molecules used for CEA-Scan diagnosis - monoclonal antibodies - as a new treatment modality that may enhance the prospects of chemotherapy, external-beam irradiation, and other biological agents in current use or under development.

If you are a patient seeking information on colorectal cancer or CEA-Scan, please click here. The information provided to you is not intended to replace the need for you to consult with your physician with regard to your particular case. Please see our Legal Statement.

Click here for Physician Information pertinent to Colorectal Surgery, Medical Oncology, Radiology, Nuclear Medicine, or Gastroenterology. Please see our Legal Statement.

For Nuclear Physician Information pertinent to colorectal cancer or CEA-Scan, click here. Please see our Legal Statement.

Information contained herein, in addition to historical, contains certain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirement/actions), competitive risks to marketed products and availability of financing and other sources of capital as well as those discussed in the Company’s Annual Report on Form 10-K for the year ended June 30, 1998.

©Copyright 2000 Immunomedics, Inc. The reader is directed to read the Legal Statement contained herein, and by continuing to read the contents of this web site agrees with and accepts the conditions and statements of these disclaimers.